Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple 4SCAR-T Cell Therapy Targeting Breast Cancer
NCT04430595Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 4SCAR19 in breast cancer, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Number of patients with adverse events at 3 years. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
4SCAR19
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04430595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430595.